期刊名称：JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
The Journal of Trauma and Acute Care Surgery® is published 12 times per year by Lippincott Williams & Wilkins in two volumes beginning in January and July. Content focuses specifically on traumatic injuries giving the reader hands-on coverage of this fast-growing specialty. Articles cover everything from the nature of the injury to the effects of new drug therapies...from recommendations for more effective surgical approaches to the latest laboratory findings.
Previously known as
The Journal of Trauma Injury Infection and Critical Care
Sponsored by
Official Publication of
Instructions to Authors
I. ABOUT THE JOURNAL
♦ SCOPE ♦
The Journal of Trauma and Acute Care Surgery is a peer-reviewed, multidisciplinary journal directed to an audience of trauma physicians. The Journal welcomes submissions from all sources and all countries that contribute to the scientific knowledge of the management of trauma, emergency surgery, and the care of critically ill patients.
♦ EDITORIAL POLICIES ♦
Ethical & Legal Considerations
A submitted manuscript must be an original contribution not previously published (except as an abstract or a preliminary report); must not be under consideration for publication elsewhere; and, if accepted, must not be published elsewhere in similar form, in any language, without the consent of Lippincott Williams & Wilkins. Each author must have contributed significantly to, and be willing to take public responsibility for, one or more aspects of the study: its design, data acquisition, and analysis and interpretation of data. All authors must have been actively involved in the drafting and critical revision of the manuscript, and each must provide final approval of the version to be published. Individuals who have contributed to only one section of the manuscript or have contributed only clinical cases should be credited in an acknowledgement footnote.
Although the editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with the Journal, its editors, or the publisher. Authors must submit manuscripts on-line through the Journal's website at www.editorialmanager.com/jt. Submission instructions are listed in the Manuscript Submission section below.
Patient Anonymity and Informed Consent
It is the author's responsibility to ensure that a patient's anonymity is carefully protected, to verify that any experimental investigation with human subjects reported in the manuscript was performed with informed consent, and follows all the guidelines for experimental investigation with human subjects required by the institution(s) with which all the authors are affiliated.
Authors are asked to comply with the U.S. Department of Health and Human Services’ HIPAA
Privacy Rule, and particularly those provisions concerned with the protection of health information in research (more information can be found at http://www.hhs.gov/ocr/privacy/hipaa/understanding/special/research/). Authors should mask patients' eyes and remove patients' names from figures, unless written consent from the patients has been obtained and can be submitted with the manuscript.
Accessibility & Compliance with Research Funding Agencies
A number of research funding agencies now require or request authors to submit the post-print (the article after peer review and acceptance, but not the final published article) to a repository that is accessible online by all without charge. As a service to our authors, LWW will identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the post-print of an article based on research funded in whole or in part by the National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The Copyright Transfer/Public Access Policy/Financial Disclosure form completed and signed with each submission functions as a mechanism for this action.
Permissions
Authors must submit written permission from the copyright owner (usually the publisher) to use lengthy quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, along with complete details about the source. Any permission fees that might be required by the copyright owner are the responsibility of the authors requesting use of the borrowed material, and are not the responsibility of the Journal or Lippincott Williams & Wilkins.
Research Integrity
The Journal of Trauma and Acute Care Surgery requests that authors take note of and adhere to guidelines established by the U.S. Department of Health and Human Services Office of Research Integrity ( http://ori.dhhs.gov/). The Journal itself is a member of the Committee on Publication Ethics (COPE) ( http://publicationethics.org/), and editors will investigate suspected instances of scientific fraud, inappropriate image manipulation, plagiarism, duplicate publication and other cases that violate research ethics. Depending on the outcome of these investigations, the Journal may decide to publish errata, or, in cases of serious scientific misconduct, ask authors to retract their paper or to impose retraction on them.
If an important error is made by the author(s) or journal, please contact the editorial office to initiate production of a formal erratum.
II. MANUSCRIPT PREPARATION
Manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.
♦ STUDY QUALITY GUIDELINES ♦
The Journal of Trauma and Acute Care Surgery respectfully requests that its prospective authors follow international reporting standards when documenting study methods. To find guidelines for a particular study design, please consult the resources below or see the EQUATOR Network’s library of reporting guidelines.
Reporting Clinical Trials
The Journal follows the WHO definition of a clinical trial:
"A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc."
The Journal supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration. All trials initiated after 1 July 2005 must be registered prospectively in a publicly accessible registry (i.e., before patient recruitment has begun), or they will not be considered for publication. Authors must state the registry in the first paragraph of the Methods section of the manuscript. As of January 1, 2008, all clinical trials involving investigational drugs supported by a pharmaceutical company or investigational devices supported by a device manufacturer must be registered at the time that a manuscript is submitted for publication. As of January 1, 2009, all clinical trials involving investigational drugs or devices supported by a pharmaceutical firm or device manufacturer that began after January 1, 2008 must be registered prior to patient enrollment.
For more information, please see the ICMJE’s FAQ on trial registration and the WHO's list of approved registries at http://www.who.int/ictrp/network/primary/en/index.html.
Authors of trials must adhere to the CONSORT reporting guidelines appropriate to their trial design. Please check the CONSORT statement website for information on the appropriate guidelines for specific trial types. Before the paper can enter peer review authors must:
1) provide the trial name as it appears in the registry, trial registration number, and IRB number and
2) provide a copy of the completed CONSORT flow diagram as a supporting file (this diagram will be published alongside the paper, if accepted).
The CONSORT flow diagram must be included as a figure. This CONSORT diagram will be included in the published version of your manuscript and, as such, will count as one of your figures (for more information regarding figure limits, please see III. Manuscript Types and Content Limits below). Moreover, any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss informed consent in their paper, and the Journal’s editorial office reserves the right to ask for a copy of the patient consent form(s). Information on statistical methods or participants beyond what is indicated in the CONSORT statement should be reported in the Methods section.
The Journal supports the public disclosure of all clinical trial results, as mandated by the FDA Amendments Act of 2007. Prior disclosure of results on a public web site such as http://clinicaltrials.gov will not affect the decision to proceed to peer review or accept papers at the Journal of Trauma and Acute Care Surgery.
Systematic Reviews and Meta-Analyses
Reports of systematic reviews and meta-analyses should use the PRISMA statement as a guide, and include a completed PRISMA checklist and flow diagram to accompany the main text. Blank templates of the checklist and flow diagram can be downloaded from the PRISMA website. Authors must also state within the Methods section of their paper whether a protocol exists for their systematic review, and if so, provide a copy of the protocol as supporting information. The Journal supports the prospective registration of systematic reviews. Authors whose systematic review was prospectively registered (e.g. in a registry such as PROSPERO) should also provide the registry number in their abstract. Registry details and protocols will be made available to editors and reviewers, and will be included alongside the paper for readers if the report is ultimately published.
Reporting Diagnostic Studies
Reports of studies of diagnostic accuracy should conform to the STARD requirements.
Reporting Observational Studies
For reports of observational studies (cohort, case-control, or cross-sectional designs), please consult the STROBE statement.
Reporting Microarray Experiments
Reports of microarray experiments should conform to the MIAME guidelines, and the data from the experiments must be deposited in a publicly accessible database.
♦ LEVELS OF EVIDENCE ♦
The Journal of Trauma and Acute Care Surgery requires authors to describe their study and include an assessment of their conclusion(s) by indicating the Levels of Evidence and study type at the end of their abstract. To determine the level under which a study falls, please consult the following table:
Evidence Levels for Individual Studies (J Trauma Acute Care Surg. 2012;72(6):1484-90)
| |
Therapeutic / Care
Management |
Prognostic and Epidemiological |
Diagnostic Tests or Criteria |
Economic & Value-based Evaluations |
Systematic Reviews & Meta-analyses |
| Level I |
RCT with no negative criteria* |
Prospective† study with large effect† and no negative criteria* |
Testing of previously developed diagnostic criteria in consecutive patients (all compared to "gold" standard) and no negative criteria. |
Sensible costs and alternatives; values obtained from many sources; multi- way sensitivity analyses |
Systematic Review (SR) or meta-analysis (MA) of predominantly level I studies and no SR/MA negative criteria † |
| Level II |
• RCT with significant difference and only one negative criterion*
• Prospective† comparative study without negative criteria*
• Prospective/retrospective† study with large effect‡ and only one negative criterion*
|
• Prospective† study with less than large effect‡ and no negative criteria*
• Untreated controls from RCT |
Development of diagnostic criteria on consecutive patients (all compared to "gold" standard) and only one negative criterion. |
Sensible costs and alternatives; values obtained from limited sources; multi- way sensitivity analyses |
SR / MA of predominantly level II studies with no SR/MA negative criteria † |
| Level III |
• ase-control study without negative criteria*
• Prospective† comparative study with only one negative criterion*
• Retrospective† comparative study without negative criteria*
|
• Case-control study without negative criteria *
• Prospective/retrospective† study with up to two negative criteria* |
Nonconsecutive patients (without consistently applied "gold" standard) with up to two negative criteria. |
Analyses based on limited alternatives and costs; poor estimates |
SR /MA with up to two negative criteria † |
| Level IV |
Prospective/retrospective† study using historical controls or having more than one negative criterion* |
Prospective/retrospective† study with up to three negative criteria* |
Case-control study with no negative criteria* or other designs with up to three negative criteria. |
No sensitivity analyses |
SR/MA with more than two negative criteria † |
| Level V |
• Case series
• Studies with quality worse than level IV |
• Case series
• Studies with quality worse than level IV |
No or poor "gold" standard |
|
|
* Negative criteria decreasing level of evidence include: (1) <80% follow-up; (2) >20% missing data or missing data not at random without proper use of missing data statistical techniques; (3) limited control of confounding (e.g., mortality comparisons with inadequate risk adjustment); (4) more than minimal bias (selection bias, publication bias, report bias, etc.); (5) heterogeneous populations (e.g., institutions with distinct protocols/patient volume, conditions caused by distinct pathogenic mechanisms); and (6) for RCT only, no blinding or improper randomization; (7) Inadequate statistical power: this only applies to studies NOT finding statistical differences and it is defined as power <80% for declaring “ failure to detect a significant difference” or power <90% for declaring “bio-equivalence or non-inferiority or comparative effectiveness” or Receiver Operating Characteristic curve <80% or both sensitivity and specificity <80%.
† Prospective versus retrospective: studies with data collected to answer predefined questions are prospective; studies with data collected for questions unrelated to the original question for which the data were gathered are retrospective.
‡ Large effect is defined as: (1) study with large RR (95 or 0.2) about condition of low-to-moderate morbidity/mortality and (2) study with moderate-to-large RR (2Y5 or 0.2Y0.5) about condition of high morbidity/mortality. Large effect includes the following: (1) study with large RR (95 or G0.2) about condition of low-to-moderate morbidity/mortality and (2) study with moderate-to-large RR (>5 or <0.2) about condition of high morbidity/mortality.
§ Negative criteria for SR/MS (decreases level of evidence): (1) no or inadequate standard search protocol, (2) more than minor chance of publication bias or publication bias not assessed, (3) moderate heterogeneity of included studies and/or populations (e.g., elective operation and acute operation), (4) predominance of level III or lower studies, and (5) no measures or inappropriate measures of pooled risk (for meta-analysis only).
ǁ Adequate statistical power: this only applies to studies not finding statistical differences, and it is defined as power 980% for declaring ‘‘failure to detect a significant difference’’ or power 990% for declaring ‘‘bioequivalence or noninferiority or comparative effectiveness.’’
In addition to the level, studies will receive a + to designate whether standard reporting format was followed (e.g., CONSORT for RCTs). Authors can find reporting guidelines for most studies at the international EQUATOR Network.
♦ REQUIRED COMPONENTS ♦
Conflicts of Interest Statement
Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared. All sources of funding should be acknowledged in the manuscript. All relevant conflicts of interest and sources of funding should be included on the title page of the manuscript with the heading “Conflicts of Interest and Source of Funding.” For example:
Conflicts of Interest and Source of Funding: Author A has received honoraria from Company 1. Author B is currently receiving a grant (#12345) from Organization Y, and is on the speaker’s bureau for Organization X – the CME organizers for Company 1. For the remaining authors, no conflicts were declared.
Copyright Transfer Form
In addition, each author must complete and submit the Journal’s copyright transfer agreement, which includes a section on the disclosure of potential conflicts of interest based on the recommendations of the International Committee of Medical Journal Editors, “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” ( www.icmje.org/update.html). The form is readily available on the manuscript submission page and can be completed and submitted electronically. Please note that authors may sign the copyright transfer agreement form electronically. For additional information about electronically signing this form, go to http://links.lww.com/ZUAT/A106.
Protection of Human Subjects & Animals in Research
For original articles in the Journal that report on research involving animals, the corresponding author must confirm that all experiments were performed in accordance with relevant guidelines and regulations (i.e. IACUC guidelines and federal regulations). The manuscript must include a statement identifying the institutional and/or licensing committee approving the experiments, along with any relevant details. When documenting animals studies, we recommend adhering to the ARRIVE reporting guidelines (PLoS Bio 8(6), e1000412,2010).
When reporting experiments on human subjects, authors must identify the IRB committee approving the experiments, and include with their submission a statement confirming that informed consent was obtained from all subjects. If no legally informed consent can be obtained, such as in research carried out with human subjects receiving emergency treatment, authors should indicate that a waiver of regulatory requirements for obtaining and documenting informed consent applies (in accordance with the U.S. HHS federal guidance). More information regarding the journal’s standards on protecting the welfare of human subjects in research can be accessed from the U.S. Department of Health and Human Services Office for Human Research Protections.
III. MANUSCRIPT TYPES AND CONTENT LIMITS
Please review the following descriptions of manuscript types and the required article lengths, illustrations and table limits, and references counts. Manuscripts should be as succinct as possible.
|
Manuscript Type |
Abstract Style |
Word Limit |
Figure/Table Limit |
Reference Limit |
SDC* Accepted? |
|
Original Articles |
Structured |
3,000 |
6 |
40 |
Yes |
|
Review Articles |
None |
5,000 |
8 |
100 |
Yes |
|
Guidelines |
None |
5,000 |
8 |
100 |
Yes |
|
Proceedings |
None |
8,000 |
0 |
150 |
Yes |
|
Current Opinions |
None |
2,000 |
6 |
40 |
Yes |
|
Procedures and Techniques |
None |
2,000 |
8 |
20 |
Yes |
|
Brief Reports |
Structured |
2,000 |
6 |
20 |
Yes |
|
Letters to the Editor |
None |
1,000 |
0 |
5 |
No |
|
Special Reports† |
None |
3,000 |
6 |
40 |
Yes |
|
Editorial Critique† |
None |
350 |
0 |
0 |
No |
|
Book Reviews† |
None |
500 |
0 |
0 |
No |
- * Supplemental Digital Content
- † Solicited by the editor only
Please review the following descriptions of manuscript types and the required article lengths, figure and table limits, and references counts. Manuscripts should be as succinct as possible. Please note that Case Reports and Images of Trauma are no longer published by the Journal.
Original Articles
Original articles contain original clinical or laboratory investigations. These articles should include a clearly-stated objective and hypothesis and information on study design and methodology, participation, interventions, outcome measurements, and study results. A discussion section should place the paper in context with related studies and the conclusions should be supported by the data presented. Authors must indicate a level of evidence and study type in the abstract as outlined above. Please note: systematic reviews and meta-analyses are considered original articles. Original articles must include a structured abstract and are limited to 3,000 words with six tables/figures and 40 references.
Review Articles
Review articles provide a critical assessment of the literature pertaining to a specific topic and synthesize the data to provide an overview of our current understanding of the subject. Review articles should highlight areas of consensus as well as controversy. To minimize the risk of duplicating effort, prospective authors are encouraged to query to the editorial office before embarking on the composition of a review. Review articles do not require an abstract, but are limited to 5,000 words with eight tables/figures and 60 references.
Guidelines
These articles represent consensus-based clinical practice guidelines with appropriate references to support the recommendations. Recommendations should be graded to indicate the level of evidence. Guidelines do not require an abstract, but are limited to 5,000 words with eight tables/figures and 100 references.
Proceedings. Conference proceedings may be submitted directly to the Editor for consideration. Proceedings are limited to 8,000 words with 150 references.
Current Opinions
These papers present the unique perspectives of contributors in articles that are not rigorously scientific and may include topics indirectly related to clinical practice or laboratory investigations that are of special interest to the readership. Current Opinions are limited to 2,000 words with six tables/figures and 40 references.
Procedures and Techniques
These papers describe clinical or experimental experiences that demonstrate innovative uses of technology or novel approaches to common problems. Case reports describing the clinical management of unusual problems will not be considered. Procedures and Techniques articles do not require an abstract, and are limited to 2,000 words with six tables/figures and 20 references.
Brief Reports
Brief Reports provide short descriptions of clinical or laboratory research observations that are not sufficiently developed to scientifically test hypotheses. Brief reports are presented as a shorter version of an original article (maximum 2,000 words with six tables/figures and 20 references), include a structured abstract, and typically provide observations that point to further study. These articles are not case reports – clinically-oriented Brief Reports should provide synthesized results rather than the narrative description of unusual cases.
Special Reports
Special Reports are solicited by the Editor-in-Chief and directed to knowledgeable experts in a particular field. Special Reports do not require an abstract and are limited to 3,000 words with six tables/figures and 40 references.
Editorial Critique
A brief editorial critique of an original article is occasionally solicited by the Editor or submitted by the Association from a meeting where the paper was presented. Editorial Critiques must be no longer than 350 words.
Letters to the Editor
Letters submitted to the Editor should contain a brief and thoughtful analysis of an original article. Please note that selected letters will be published at the Editor’s discretion. References, if appropriate, can be provided. Letters to the Editor should be no longer than 500 words.
IV. NECESSARY FILES FOR SUBMISSION
- Copyright Transfer/Financial Disclosure Form
All authors must complete, sign, and submit a Copyright Transfer/Public Access Policy/Financial Disclosure form with their submission before the editorial review process will begin.
- Cover Letter – Your cover letter should include:
Full title.
Type of paper (see section III. Manuscript Types above for a full list of paper types). Include a section category, if manuscript was or will be presented at a conference. Confirmation that your submission has not been published elsewhere.
Corresponding Author's contact information.
For Revisions, your Cover Letter must include a point-by-point discussion addressing each of the reviewer's comments (see section VII. Manuscript Submission below for details).
- Title Page - The Title Page should include:
Complete manuscript title.
Short title (running head) of not more than 45 characters. Authors' full names, highest academic degrees, and affiliations.
E-mail addresses for all authors (please provide telephone numbers or mailing addresses for authors who do not have e-mail addresses).
Name and address for correspondence, including fax number, telephone number, and e-mail address.
Address for reprints, if different from that of corresponding author.
Conflict of interest statement detailing all sources of support, including pharmaceutical and industry support. If no conflicts are declared, this must also be stated.
List of meetings at which the paper was presented, if any.
Disclosures of funding received for this work from any of the following organizations: National Institutes of Health (NIH); Wellcome Trust; and the Howard Hughes Medical Institute (HHMI).
- Structured Abstract with Key Words (when required) – Please:
Submit your abstract as a separate file.
Limit the abstract to 300 words.
Limit the use of abbreviations and acronyms; do not cite references.
Use the following subheads: Background, Methods, Results, Conclusions, and Level of
Evidence.
Indicate study type (prognostic, therapeutic, diagnostic test, economic/decision) after level. List three to five keywords.
- Text – Your manuscript must include:
Four main headings (for content with structured abstracts): Background, Methods, Results, and
Discussion.
Define abbreviations at first mention in text and in each table and figure. If a brand name is cited, supply the manufacturer's name and address (city and state/country).
Please include an Author Contribution statement detailing the contribution each author made to the study (e.g. literature search, study design, data collection, data analysis, data interpretation, writing, critical revision, etc) under a separate heading, before the references. Acknowledgments may also be included.
All reference citations must be cited sequentially within the article and in the references.
Follow the limits for the maximum number of words, tables and references for your manuscript type (see section III. Manuscript Types above).
V. STYLE AND FORMATTING GUIDELINES
♦ GENERAL FORMATTING GUIDELINES ♦
Please submit your manuscript in accordance with the following requirements:
Create your manuscript with MS Word (save as DOC file).
Use Times New Roman, 12 point for the main text. Format your paper with 1-inch margins, double-spaced, and numbered pages.
Tables and figures cannot be embedded within the text.
Tables can be included at the end of the document.
Figures must be submitted as separate TIFF, EPS, or MS Office (DOC, PPT, XLS) files. High resolution PDF files are also acceptable.
Photos should be submitted according to the resolution requirements below. Please crop out any patient identifiers, unwanted text, and excessive white space.
Diagrams, drawings and graphs must have a resolution of at least 1200 dpi (dots per inch).
For photographs and radiographs with text, set the resolution to at least 600 dpi.
Photographs, radiographs and other halftone images must have a resolution of at least 300 dpi.
Do not submit ASCII text files.
Do not use automatic numbering or footnotes for references.
♦ FIGURES ♦
All figures must be submitted in a separate file from the text file.
Each figure is limited to a maximum of four parts or panels. Multi-panel images that do not abide by this limit will be placed online as supplemental digital content.
List figures numbers, consecutively, within the text and online submissions.
Figure labels should include figure number, or figure parts, title of figure, with brief and specific descriptions (if any).
Lettering should be large enough that it will remain legible after figure reduction.
Figure parts (A, B, C, D) may be left unlabeled (but clearly marked in the figure legend) for design layout by the Journal's publisher.
For detailed information concerning figure specifications, please see VI. Creating Digital Artwork below.
Figure Legends
Include legends for all figures in the figure file.
Figure legends should appear on a separate page before the actual figures.
Legends should be brief and specific.
For electron micrographs, please use scale markers in the image and indicate the type of stain used.
Color Figures
Color figures are accepted that will enhance an article.
Authors who submit color figures will receive an estimate of the cost for color reproduction.
If authors decide not to pay for color reproduction, the figures will be converted to black and white at no charge.
Tables
Use the table creating/editing features in MSWord or WordPerfect.
Do not embed tables within the body of the manuscript.
Do not use Excel or comparable spreadsheet programs.
Group all tables in a separate file or at the end of the text.
Cite tables consecutively in the text.
Each table must appear on a separate page and should include the table title, appropriate column heads, and explanatory legends (include definitions of any abbreviations used).
Tables should be self-explanatory and supplement, rather than duplicate, the material in the text.
♦ HOUSE STYLE ♦
Pattern manuscript style after the American Medical Association Manual of Style (10 th edition). Stedman's Medical Dictionary (27th edition) and Merriam Webster's Collegiate Dictionary (10th edition) should be used as standard references.
Refer to drugs and therapeutic agents by their accepted generic or chemical names; do not abbreviate them.
Use code numbers only when a generic name is not yet available. In that case, it is required to supply the chemical name and include a figure giving the chemical structure of the drug.
Copyright or trade names of drugs should be capitalized and placed in parentheses after the name of the drug.
Names and locations (city and state in USA; city and country outside USA) of manufacturers of drugs, supplies, or equipment cited in a manuscript are required to comply with trademark law and should be provided in parentheses.
Units of measure should be expressed in the metric system.
Temperatures should be expressed in degrees Celsius.
Conventional units should be written as SI units, as appropriate.
Abbreviations
Write out the full term for each abbreviation at its first use, unless it is a standard unit of measure. For a list of standard abbreviations, consult the Council of Biology Editors Style Guide (available from the Council of Science Editors, 9650 Rockville Pike, Bethesda, MD 20814) or other standard editorial resources.
References
The authors are responsible for the accuracy of the references.
References must be (double-spaced) at the end of the manuscript.
Cite the references in text in the order of appearance.
Cite unpublished data – such as papers submitted, but not yet accepted for publication, and personal communications (including e-mail) – in parentheses in the text.
Please list all authors. However, if a reference contains more than ten contributors, name only the first ten authors and then use et al. If a reference cites a consortium or multi-center trials group, list up to ten authors followed by et al. and the official name of the study group.
If you are using EndNote to format your references, please use the Vancouver style template and modify this to include up to 10 authors.
Refer to the “List of Journals Indexed in Index Medicus” for abbreviations of journal names, or access the list at http://www.nlm.nih.gov/tsd/serials/lji.html.
Sample references are given below:
Journal article
- Teixeira PG, Inaba K, Shulman I, Salim A, Demetriades D, Brown C, Browder T, Green D, Rhee P. Impact of plasma transfusion in massively transfused trauma patients. J Trauma. 2009;66:693-697.
- Burlew CC, Moore EE, Cuschieri J, Jurkovich GJ, Codner P, Crowell K, Nirula R, Haan J, Rowell SE, Kato CM, et al. and the WTA Study Group. Sew it Up! A Western Trauma Association Multi-Institutional Study of Enteric Injury Management in the Postinjury Open Abdomen. J Trauma. 2011;70:273-277.
Journal article Epub Ahead of Print
Ogilvie MP, Pereira BM, Ryan ML, Gomez-Rodriguez JC, Pierre EJ, Livingstone AS, Proctor KG. Bispectral index to monitor propofol sedation in trauma patients. J Trauma. Epub 2011 Jul 15.
Book chapter
Neff LP and Chang MC. Hemodynamic Management and Shock. In: Flint L, Meredith JW, Schwab CW, Trunkey DD, Rue L, Taheri PA. eds. Trauma: Contemporary Principles and Therapy. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:675-683.
Entire book
Peitzman AB, Rhodes M, Schwab CW, Yealy DM, Fabian TC. Trauma Manual: Trauma and Acute Care Surgery. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
Database
National Center for Injury Prevention and Control (NCIPC). National Violent Death Reporting System. Available at: http://www.cdc.gov/ViolencePrevention/NVDRS/index.html. Centers for Disease Control and Prevention. Atlanta, GA. Accessed August 15, 2011.
Web Sites
National Heart Lung and Blood Institute. Body Mass Index (BMI) Calculator. Available at: http://www.nhlbisupport.com/bmi. Accessed August 15, 2011.
VI. CREATING DIGITAL ARTWORK
To ensure the highest-quality reproduction of figures, please follow these guidelines carefully. Please also note that the Journal of Trauma and Acute Care Surgery is not responsible for the quality of images in print; it is the responsibility of authors to submit publication-quality, high-resolution images. If you have questions, consult a graphics specialist.
♦ CREATING AND SAVING FILES ♦
Learn about the publication requirements for Digital Artwork: http://links.lww.com/ES/A42
Create, Scan and Save your artwork and compare your final figure to the Digital Artwork Guideline Checklist (below).
Upload each figure to Editorial Manager in conjunction with your manuscript text and tables.
♦ DIGITAL ARTWORK GUIDELINE CHECKLIST ♦
Here are the basics to have in place before submitting your digital artwork:
Artwork should be saved as TIFF, EPS, or MS Office (DOC, PPT, XLS) files. High resolution PDF files are also acceptable.
Crop out any white or black space surrounding the image.
Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution of at least 1200 dpi. If created in an MS Office program, send the native (DOC, PPT, XLS) file.
Photographs, radiographs and other halftone images must be saved at a resolution of at least 300 dpi.
Photographs and radiographs with text must be saved as postscript or at a resolution of at least 600 dpi.
Each figure must be saved and submitted as a separate file. Figures should not be embedded in the manuscript text file.
♦ SUBMITTING FIGURES ♦
Attach a separate file for each individual art submission.
Upload figures consecutively to the Editorial Manager web site and enter figure numbers consecutively in the Description field when uploading the files (e.g. Figure 1, Figure 2). This will label each figure in the PDF generated by Editorial Manager.
Editorial Manager will automatically perform a quality check of all figures submitted. If your figures do not pass the quality check, your manuscript will be returned to you for correction.
Carefully review the PDF conversion of your submitted files to ensure that figures upload without error and appear as intended.
♦ FIGURE LEGENDS ♦
Legends for all figures should be brief, specific, and appear on a separate page at the end of the manuscript, following the list of references.
Legends must be numbered consecutively. Indicate corresponding figure numbers. All symbols or abbreviations appearing in an illustration must be defined in the legend.
Credit for any previously published illustration must be given in the corresponding legend.
For further information on figure legend formatting, please consult the AMA Manual of Style: A Guide for Authors and Editors, 10th Edition.
VII. SUPPLEMENTAL DIGITAL CONTENT
Authors of appropriate manuscript types may submit Supplemental Digital Content (SDC) to enhance their article's text and to be considered for online-only posting.
SDC may include the following types of content: text documents, graphs, tables, figures, graphics, illustrations, audio, and video.
If an article with SDC is accepted, our production staff will create a URL with the SDC file. The URL will be placed in the call-out within the article.
Cite all Supplemental Digital Content consecutively in the text Citations should:
o include the type of material submitted.
o be clearly labeled as "Supplemental Digital Content or (SDC)."
o include a sequential number.
o provide a brief description of the SDC. Please provide a legend of SDC at the end of the text.
List each legend in the order in which the material is cited in the text. The legends must be numbered to match the citations from the text. Include a title and a brief summary of the SDC content.
For audio and video files, please include: the author name, videographer, participants, length (minutes), and size (MB).
Authors who include patient images in their work must obtain written permission from the patients and submit this permission with the manuscript. Authors must mask patients' eyes and remove patients' names from supplemental digital content, unless written consent has been obtained from patients and can be submitted with the content.
Copyright Transfer/Public Access Policy/Financial Disclosure and Permission forms for article content including SUPPLEMENTAL DIGITAL CONTENT must be completed at the time of submission in order for your submission to be considered for editorial review.
Please note: SDC files are not copyedited by LWW staff; they will be presented digitally as submitted.
♦ DIGITAL FILE SIZE & TYPE ♦
Maximum file size for all supplemental digital content: 10 MB each.
Documents, graphs, and tables may be presented in any format.
Figures, graphics, and illustrations may be submitted with the following file extensions:.tif,.eps, .ppt,.jpg,.pdf,.gif.
Audio files may be submitted with the following file extensions:.mp3,.wma
Video files may be submitted with the following file extensions:.wmv,.mov,.qt,.mpg,.mpeg, .mp4
Video files should also be formatted with a 320 X 240 pixel minimum screen size.
For more information, please review LWW's requirements for submitting supplemental digital content: http://links.lww.com/A142.
VIII. MANUSCRIPT SUBMISSION
All manuscripts must be submitted through the web-based tracking system at http://www.editorialmanager.com/jt/.
♦ FIRST-TIME USERS ♦
Please click the Register button at http://www.editorialmanager.com/jt/. Upon successful registration, you will be sent an email containing your user name and password. Print a copy of this information for future reference.
If you have already registered with us, as either a reviewer or an author, please do not register again. You may log in using your assigned user ID and password. If you have forgotten your user name and/or password, use the Forgot Your Password? link on the journal’s manuscript submission site ( http://www.editorialmanager.com/jt/).
♦ AUTHORS ♦
Please click the Login button at the top of the page and log in to the system as an author. Submit your manuscript in accordance with the author instructions. You will be able to track the progress of your manuscript through the system.
If you experience any problems with the system, please contact the Editorial Office by phone at +1 303-602-1816 or by email at jcrebs@jtrauma.org
♦ SUBMITTING A REVISION ♦
- With the revised submission, authors must submit a cover letter that lists all revisions and corrections made to the original submission that addresses each of the reviewer's concerns.
- In the text, all revisions must be highlighted or use MSWord’s “Track Changes” tool to show changes and corrections to the original version.
- When submitting your revision, you must also include a separate final, revised document, in addition to your revised document with all visible changes.
♦ SUBMITTING SUPPLEMENTAL DIGITAL CONTENT♦
On the “Attach Files” page of the submission process, please select “Supplemental Audio, Video, or Data” for your uploaded file as the submission item.
IX. AFTER ACCEPTANCE
- PAGE PROOFS & CORRECTIONS ♦
Before publication, corresponding authors will receive electronic page proofs to check the copyedited and typeset article.
Portable document format (PDF) files of the typeset pages and support documents (e.g., reprint order form) will be e-mailed to the corresponding author.
Complete instructions will be provided with the e-mail for downloading, printing the files, and for faxing corrected page proofs to the publisher.
Authors without an e-mail address will receive traditional page proofs.
It is the author's responsibility to ensure that there are no errors in the proofs.
Changes that have been made to conform to journal style will stand, if they do not alter the authors' meaning.
Only changes that are critical to the accuracy of the content will be accepted.
Changes that are stylistic or are a reworking of previously accepted material will be disallowed.
The publisher reserves the right to deny any changes that do not affect the accuracy of the content.
Authors may be charged for alterations to the proofs beyond those required to correct errors or to answer queries.
Proofs must be checked carefully and corrections faxed within 24 to 48 hours of receipt, as requested, in the cover letter accompanying the page proofs.
- REPRINTS ♦
Authors will receive a reprint order form and a price list with the page proofs.
Reprint requests should be faxed to the publisher with the corrected proofs, if possible.
Reprints normally ship 6 to 8 weeks after publication of the issue in which the item appears.
Contact the Author Reprint Department, Lippincott Williams & Wilkins, 351 W. Camden Street, Baltimore, MD 21201 with questions, (410) 528-4077, Fax: (410) 528-4434.
X. CONTACTS
♦ EDITORIAL OFFICE ♦
General
Journal of Trauma and Acute Care Surgery, 655 Broadway, Suite 365, Denver, CO 80204, Fax: (303) 602-1817, Email: info@jtrauma.org.
Editorial Contacts
For editorial questions regarding scientific quality, suitability, and content of articles submitted to the Journal, please contact the Editor-in-Chief, Ernest E. Moore, MD at emoore@jtrauma.org.
Please direct any questions concerning regarding the electronic submission system, editorial decisions, appeals, peer-review concerns, supplements, or production to Jennifer Crebs, Managing Editor, at jcrebs@jtrauma.org or at (303) 602-1816.
For questions concerning manuscript submission requirements or the status of a paper under review, please contact Jo Fields, Assistant Editor, at jfields@jtrauma.org or (303) 602-1815.
♦ PUBLISHER ♦
Publisher
John Ewers, Senior Publisher, Lippincott Williams & Wilkins, 351 W. Camden St., Baltimore, MD 21201; Tel: (410) 528-4088; Email: john.ewers@wolterskluwer.com.
Production
Dinah Elashvili, Production Editor, Lippincott Williams & Wilkins, 351 W. Camden St., Baltimore, MD 21201; Tel: (410) 528-4070; Fax: (443) 451-8198, Email: dinah.elashvili@wolterskluwer.com.
Advertising
Display ads: Bethann Sands, Tel: (215) 521-8399, Email: bethann.sands@wolterskluwer.com. Classified ads: Taron Butler, Tel: (420) 361-8003 or (800) 645-3658, Fax: (410) 558-6257, Email: taron.butler@wolterskluwer.com.
Reprints
Author Reprint Department, Lippincott Williams & Wilkins, 351 W. Camden Street, Baltimore, MD 21201; Tel: (410) 528-4077, Fax: (410) 528-4434.
Subscriptions
Lippincott Williams & Wilkins, 16522 Hunters Green Parkway, Hagerstown, MD 21740; Tel: (800) 638-3030, Fax: (301) 223-2400.
XI. DISCLAIMER
The statements and opinions expressed in the Journal of Trauma and Acute Care Surgery are those of the individual contributors, editors, or advertisers, as indicated, and do not necessarily represent the views of the other editors, the publisher or the American Association for the Surgery of Trauma. Unless otherwise specified, the authors and publisher disclaim any responsibility or liability for such material.
Editorial Board
Editor
Ernest E. Moore, MD
Denver, Colorado
Managing Editor
Jennifer Crebs
Denver, Colorado
Assistant Editor
Jo Fields
Denver, Colorado
Biostatistician
Angela Sauaia, MD, PhD
Denver, Colorado
Editors Emeriti
Basil A. Pruitt, Jr., MD
San Antonio, Texas
1995–2011
John H. Davis, MD
1975–1994
William T. Fitts, Jr., MD
1969–1974
Rudolph Noer, MD
1961–1968
Charles G. Johnston, MD
Founding editor, 1960
Associate Editors
David B. Hoyt, MD
Chicago, Illinois
Ronald V. Maier, MD
Seattle, Washington
Steven R. Shackford, MD
San Diego, California
Editorial Board |
|
|
Hasan B. Alam, MD
Ann Arbor, Michigan
Jameel Ali, MD, MMed
Toronto, Ontario, Canada
Juan A. Asensio, MD
Westchester, New York
Christopher C. Baker, MD
Roanoke, Virginia
Chad Ball, MD
Calgary, Alberta
Erik Barquist, MD
Miami, Florida
Denis D. Bensard, MD
Denver, Colorado
James M. Betts, MD
Oakland, California
Walter L. Biffl, MD
Denver, Colorado
Karen Brasel, MD, MPH
Milwaukee, Wisconsin
Susan M. Briggs, MD, MPH
Boston, Massachusetts
L. D. Britt, MD
Norfolk, Virginia
Carlos V.R. Brown, MD
Austin, Texas
Eileen M. Bulger, MD
Seattle, Washington
Clay C. Burlew, MD
Denver, Colorado
Howard R. Champion, MD
Bethesda, Maryland
William G. Cheadle, MD
Louisville, Kentucky
William G. Cioffi, MD
Providence, Rhode Island
Christine S. Cocanour, MD
Sacramento, California
Thomas H. Cogbill, MD
La Crosse, Wisconsin
Mitchell J. Cohen, MD
San Francisco, California
Stephen M. Cohn, MD
San Antonio, Texas
Raul Coimbra, MD, PHD
San Diego, California
Robert N. Cooney, MD
Syracuse, New York
Martin A. Croce, MD
Memphis, Tennessee
H. Gill Cryer, MD
Los Angeles, California
Joseph Cuschieri, MD
Seattle, Washington
James W. Davis, MD
Fresno, California
Kimberly A. Davis, MD
New Haven, Connecticut
Edwin A. Deitch, MD
Newark, New Jersey
Demetrios Demetriades, MD, PhD
Los Angeles, California
Lawrence N. Diebel, MD
Detroit, Michigan
David J. Dries, MSE, MD
St. Paul, Minnesota
Thomas J. Esposito, MD, MPH
Maywood, Illinois
Timothy C. Fabian, MD
Memphis, Tennessee
Samir M. Fakhry, MD
Charleston, South Carolina
David V. Feliciano, MD
Indianapolis, Indiana
Lewis M. Flint, MD
Chicago, Illinois
Charles J. Fox, MD
Bethesda, Maryland
Heidi Frankel, MD
Pasadena, California
Donald E. Fry, MD
Chicago, Illinois
David G. Greenhalgh, MD
Sacramento, California
Brian Harbrecht, MD
Louisville, Kentucky
Carl J. Hauser, MD
Boston, Massachusetts
David N. Herndon, MD
Galveston, Texas
John B. Holcomb, MD
Houston, Texas
Kenji Inaba, MD
Los Angeles, California
Rao R. Ivatury, MD
Richmond, Virginia
Lenworth M. Jacobs, MD
Hartford, Connecticut
Marc Jeschke, MD, PhD
Toronto, Ontario
Gregory J. Jurkovich, MD
Denver, Colorado |
Riyad Karmy-Jones, MD
Vancouver, Washington
Lewis J. Kaplan, MD
New Haven, Connecticut
Jeffry L. Kashuk, MD
Dallas, Texas
Fernando Kim, MD
Denver, Colorado
M. Margaret Knudson, MD
San Francisco, California
Rosemary A. Kozar, MD
Houston, Texas
Frank R. Lewis, MD
Philadelphia, Pennsylvania
David H. Livingston, MD
Newark, New Jersey
Charles E. Lucas, MD
Detroit, Michigan
Fred A. Luchette, MD
Maywood, Illinois
Robert C. Mackersie, MD
San Francisco, California
Ajai K. Malhotra, MD
Richmond, Virginia
Kenneth L. Mattox, MD
Houston, Texas
Norman E. McSwain, Jr., MD
New Orleans, Louisiana
J. Wayne Meredith, MD
Winston-Salem, North Carolina
William J. Mileski, MD
Galveston, Texas
Joseph P. Minei, MD
Dallas, Texas
Charles N. Mock, MD
Seattle, Washington
Frederick A. Moore, MD
Gainesville, Florida
Richard J. Mullins, MD
Portland, Oregon
Lena M. Napolitano, MD
Ann Arbor, Michigan
Avery B. Nathens, MD
Toronto, Ontario
H. Leon Pachter, MD
New York, New York
Andrew B. Peitzman, MD
Pittsburgh, Pennsylvania
Hiram C. Polk, MD
Louisville, Kentucky
Kenneth G. Proctor, MD
Miami, Florida
Reuven Rabinovici, MD
Boston, Massachusetts
R. Lawrence Reed, II, MD
Indianapolis, Indiana
Peter Rhee, MD, MPH
Tucson, Arizona
J. David Richardson, MD
Louisville, Kentucky
Sandro Rizoli, MD
Toronto, Ontario
Frederick B. Rogers, MD
Lancaster, Pennsylvania
Michael F. Rotondo, MD
Rochester, New York
Grace S. Rozycki, MD
Atlanta, Georgia
Thomas M. Scalea, MD
Baltimore, Maryland
Martin A. Schreiber, MD
Portland, Oregon
George F. Sheldon, MD
Chapel Hill, North Carolina
Michael J. Sise, MD
San Diego, California
David A. Spain, MD
Stanford, California
David A. Sperry, MD, MPH
Stanford, California
Philip F. Stahel, MD
Denver, Colorado
Joseph J. Tepas, III, MD
Jacksonville, Florida
Ronald G. Tompkins, MD
Boston, Massachusetts
Lorraine Tremblay, MD
Toronto, Ontario
Donald D. Trunkey, MD
Portland, Oregon
Alex B. Valadka, MD
Austin, Texas
Dennis W. Vane, MD, MBA
St. Louis, Missouri
George C. Velmahos, MD, PhD
Boston, Massachusetts
Charles Wade, PhD
Houston, Texas
Matthew J. Wall, MD
Houston, Texas
John Weigelt, MD
Milwaukee, Wisconsin
David E. Wesson, MD
Houston, Texas
Michael A. West, MD
San Francisco, California |
International |
|
|
Zsolt J. Balogh, MD
Newcastle, Australia
Kenneth D. Boffard, MD
Johannesburg, South Africa
Karim Brohi, MD
London, United Kingdom
Susan Brundage, MD, MPH
London, United Kingdom
Ray-Jade Chen, MD
Taiwan, China
Ian Civil, MD
Auckland, New Zealand
Stephen A. Deane, MBBS
Sydney, Australia
Eugen Faist, MD
Munich, Germany
Abe Fingerhut, MD
Paris, France
Christine Gaarder, MD
Oslo, Norway
Russel L. Gruen, MBBS, PhD
Melbourne, Australia |
Kaoru Koike, MD
Kyoto, Japan
Luke Leenen, MD, PhD
Utrecht, The Netherlands
Ari K. Leppaniemi, MD
Helsinki, Finland
Jana MacLeod, MD
Nairobi, Kenya
Yasuhiro Otomo, MD, PhD
Tokyo, Japan
Hans-Christoph Pape, MD
Aachen, Germany
Renato S. Poggetti, MD
Sao Paulo, Brazil
Christian W. Schinkel, MD
Memmingen, Germany
Michael Stein, MD
Tel Aviv, Israel
Korhan Taviloglu, MD
Istanbul, Turkey |
American Association for the Surgery of Trauma |
|
President
William G. Cioffi, MD
Providence, Rhode Island
Secretary-Treasurer
Martin Croce, MD
Memphis, Tennessee
Recorder
Raul Coimbra, MD, PhD
San Diego, California
Immediate Past President
Robert C. Mackersie, MD
San Francisco, California
Past President
J. Wayne Meredith, MD
Winston-Salem, North Carolina
Past President
L.D. Britt, MD, MPH
Norfolk, Virginia
|
Board of Manager-at-Large
Heidi L. Frankel, MD
Pasadena, California
Board of Manager-at-Large
Eileen M. Bulger, MD
Seattle, Washington
Board of Manager-at-Large
Rosemary A. Kozar, MD, PhD
Houston, Texas
Critical Care Board
of Manager-at-Large
Orlando C. Kirton, MD
Hartford, Connecticut
Executive Director
Sharon Gautschy
Chicago, Illinois
|
Association Representatives |
|
|
Australian and New Zealand
Association for the Surgery of
Trauma
Zsolt J. Balogh, MD
Newcastle, Australia
Eastern Association for the
Surgery of Trauma
Juan C. Duchesne, MD
New Orleans, Louisiana |
Trauma Association of Canada
Andrew W. Kirkpatrick, MD
Calgary, Alberta
Western Trauma Association
Ajai K. Malhotra, MD
Richmond, Virginia |
|
刊名字顺( Alphabetical List of Journals):
返回页首 